Ptc Therapeutics Inc. | Mid-cap | Healthcare
$50.82
-1.78%
| Ptc Therapeutics Stock Comparison:
Ptc Therapeutics vs VertexPtc Therapeutics vs RegeneronPtc Therapeutics vs Blueprint MedicinesPtc Therapeutics vs Roivant SciencesPtc Therapeutics vs Bio-TechnePtc Therapeutics vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 806.8M
Gross Profit 749.4M 92.89%
Operating Income -146.7M -18.19%
Net Income -363.3M -45.03%
EPS (Diluted) -$4.73

Balance Sheet Metrics

Total Assets 1.7B
Total Liabilities 2.8B
Shareholders Equity -1.1B

Cash Flow Metrics

Operating Cash Flow -323.3M
Free Cash Flow -181.9M

Revenue & Profitability Trend

Ptc Therapeutics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue806.8M937.8M698.8M538.6M380.8M
Cost of Goods Sold57.4M65.5M44.7M32.3M18.9M
Gross Profit749.4M872.3M654.1M506.3M361.8M
Operating Expenses835.4M999.1M977.5M826.5M722.8M
Operating Income-146.7M-349.4M-439.9M-374.9M-397.9M
Pre-tax Income-363.1M-696.1M-587.5M-518.3M-402.9M
Income Tax176.0K-69.5M-28.5M5.6M35.2M
Net Income-363.3M-626.6M-559.0M-523.9M-438.2M
EPS (Diluted)-$4.73-$8.37-$7.79-$7.43-$6.64

Income Statement Trend

Ptc Therapeutics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets1.4B1.2B693.8M954.4M1.2B
Non-Current Assets339.5M677.1M1.0B983.7M976.5M
Total Assets1.7B1.9B1.7B1.9B2.2B
Liabilities
Current Liabilities581.0M603.1M406.2M509.3M277.3M
Non-Current Liabilities2.2B2.1B1.6B1.4B1.4B
Total Liabilities2.8B2.7B2.1B1.9B1.7B
Equity
Total Shareholders Equity-1.1B-818.6M-347.1M1.4M482.0M

Balance Sheet Composition

Ptc Therapeutics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income-363.3M-626.6M-559.0M-523.9M-438.2M
Operating Cash Flow-323.3M-423.0M-412.3M-346.8M-161.5M
Investing Activities
Capital Expenditures21.6M-28.4M-32.0M-28.2M-17.8M
Investing Cash Flow111.9M-84.6M410.6M276.3M-523.4M
Financing Activities
Dividends Paid-----
Financing Cash Flow222.1M616.4M146.9M-2.2M593.2M
Free Cash Flow-181.9M-279.0M-509.1M-336.7M-250.0M

Cash Flow Trend

Ptc Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 7.73
Forward P/E -13.67
Price to Book -20.87
Price to Sales 2.25
PEG Ratio -13.67

Profitability Ratios

Profit Margin 33.56%
Operating Margin 82.43%
Return on Equity 33.08%
Return on Assets 24.42%

Financial Health

Current Ratio 3.89
Debt to Equity -13.39
Beta 0.51

Per Share Data

EPS (TTM) $6.51
Book Value per Share -$2.35
Revenue per Share $22.95

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
ptct4.0B7.73-20.8733.08%33.56%-13.39
Vertex 114.1B32.826.92-5.64%-8.91%10.00
Regeneron 55.3B13.021.8415.96%31.94%9.20
Blueprint Medicines 8.3B-120.0024.19-47.71%-27.70%208.50
Roivant Sciences 7.8B1.951.71-12.54%96.86%1.93
Bio-Techne 7.9B60.873.926.53%10.89%20.99

Financial data is updated regularly. All figures are in the company's reporting currency.